Loading...
XKRX
003850
Market cap517mUSD
Dec 05, Last price  
9,030.00KRW
1D
-0.11%
1Q
5.12%
Jan 2017
-1.99%
Name

Boryung Corp

Chart & Performance

D1W1MN
XKRX:003850 chart
P/E
10.96
P/S
0.75
EPS
824.25
Div Yield, %
—
Shrs. gr., 5y
3.90%
Rev. gr., 5y
14.17%
Revenues
1.02t
+18.32%
197,500,614,000223,259,471,000267,844,294,000300,958,914,000308,005,546,820312,075,037,440327,278,733,560359,490,950,700401,350,239,840409,140,006,900422,721,051,680460,401,670,470524,268,670,100561,866,592,450627,279,390,050760,475,844,690859,625,585,7601,017,106,670,000
Net income
69.63b
+73.20%
8,418,563,0005,205,610,0005,182,161,00013,648,778,0006,178,116,7309,401,047,02014,126,625,32021,590,563,67020,301,086,0305,614,105,35056,698,581,46020,306,902,10032,221,802,69026,856,199,16043,044,274,38041,894,431,74040,202,797,52069,633,254,000
CFO
80.56b
+90.79%
20,223,089,00013,079,677,0003,593,431,00022,939,541,0009,185,915,50018,378,731,06028,527,119,2609,340,832,30017,114,340,7209,363,178,140-24,263,565,30038,913,967,70046,998,848,99044,740,976,18060,167,363,91027,814,064,61042,223,902,69080,557,153,000
Dividend
Dec 27, 2023100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.
URL
https://www.boryung.co.kr/en/
IPO date
Oct 24, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT